Skip to main content
NCBI home page
Atencion Primaria logoLink to Atencion Primaria
. 2013 Apr 3;34(7):374–378. [Article in Spanish] doi: 10.1016/S0212-6567(04)79519-0

Anticoagulación en pacientes con fibrilación auricular crónica: ¿cuándo indicarla?

FR García-Lizana 1,⁎, A Sarría-Santamera 1, J Gol-Freixa 1
PMCID: PMC7668626  PMID: 15511360

The content is available as a PDF (327.7 KB).

Bibliografía

  • 1.Navarro J.L., César J.M., García Avello A., Villarrubia J., López Jiménez J., Rey D. Tratamiento anticoagulante oral. Haematologia. 2001;86(Suppl 1):276–279. [Google Scholar]
  • 2.Brass L.M., Krumholz H.M., Scinto J.D., Mathur D., Radford M. Warfarin use following ischemic stroke among Medicare patients with atrial fibrillation. Arch Intern Med. 1998;158:2093–2100. doi: 10.1001/archinte.158.19.2093. [DOI] [PubMed] [Google Scholar]
  • 3.Albers G.W., Yim J.M., Belew K.M., Bittar N., Hattemer C.R., Phillips B.G. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med. 1996;156:2311–2316. [PubMed] [Google Scholar]
  • 4.Lip G.Y., Hart R.G., Conway D.S. Antithrombotic therapy for atrial fibrillation. Bmj. 2002;325:1022–1025. doi: 10.1136/bmj.325.7371.1022. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22:983–988. doi: 10.1161/01.str.22.8.983. [DOI] [PubMed] [Google Scholar]
  • 6.Connolly S.J., Laupacis A., Gent M., Roberts R.S., Cairns J.A., Joyner C. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol. 1991;18:349–355. doi: 10.1016/0735-1097(91)90585-w. [DOI] [PubMed] [Google Scholar]
  • 7.Petersen P., Boysen G., Godtfredsen J. Placebo-controlled, randomized trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK study. Lancet. 1989;1:175–179. doi: 10.1016/s0140-6736(89)91200-2. [DOI] [PubMed] [Google Scholar]
  • 8.European Atrial Fibrillation Trial Study Group Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet. 1993;342:1256–1262. [PubMed] [Google Scholar]
  • 9.Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators The effect of low-dose warfarine on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505–1511. doi: 10.1056/NEJM199011293232201. [DOI] [PubMed] [Google Scholar]
  • 10.Stroke Prevention in Atrial Fibrillation Investigators Stroke prevention in atrial fibrillation study: final results. Circulation. 1991;84:527–539. doi: 10.1161/01.cir.84.2.527. [DOI] [PubMed] [Google Scholar]
  • 11.Ezekowitz M.D., Bridgers S.L., James K.E., for the Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators Warfarin in the prevention of stroke associated with nonr-heumatic atrial fibrillation. N Engl J Med. 1992;327:1406–1412. doi: 10.1056/NEJM199211123272002. [DOI] [PubMed] [Google Scholar]
  • 12.Gullov A.L., Koefoed B.G., Petersen P., Pedersen T.S., Andersen E.D., Godtfredsen J. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998;158:1513–1521. doi: 10.1001/archinte.158.14.1513. [DOI] [PubMed] [Google Scholar]
  • 13.Hellemons B.S., Langenberg M., Lodder J., Vermeer F., Schouten H.J., Lemmens T. Primary prevention of arterial thromboembolism in non-rheumatic atrial fibrillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. Bmj. 1999;319:958–964. doi: 10.1136/bmj.319.7215.958. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Pengo V., Zasso A., Barbero F., Banzato A., Nante G., Parissenti L. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation. Am J Cardiol. 1998;82:433–437. doi: 10.1016/s0002-9149(98)00357-9. [DOI] [PubMed] [Google Scholar]
  • 15.Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. Jama. 1998;279:1273–1277. [PubMed] [Google Scholar]
  • 16.Stroke Prevention in Artrial Fibillation II Study. Warfarin versus aspirin for prevention of thromboembolism in artrial fibrillation. Lancet. 1994;343:687–691. [PubMed] [Google Scholar]
  • 17.Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996;348:633–638. [PubMed] [Google Scholar]
  • 18.Morocutti C., Amabile G., Fattapposta F., Nicolosi A., Matteoli S., Trappolini M. Indobufen versus warfarin in the secondary prevention of major vascular events in nonrheumatic atrial fibrillation. Stroke. 1997;28:1015–1021. doi: 10.1161/01.str.28.5.1015. [DOI] [PubMed] [Google Scholar]
  • 19.Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med. 1994;154:1449–1457. [PubMed] [Google Scholar]
  • 20.Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials Arch Intern Med. 1998;158:1316–1320. doi: 10.1001/archinte.158.12.1316. [DOI] [PubMed] [Google Scholar]
  • 21.The efficacy of aspirin in patients with atrial fibrillation Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. Arch Intern Med. 1997;157:1237–1240. [PubMed] [Google Scholar]
  • 22.Hart R.G., Benavente O., McBride R., Pearce L.A. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999;131:492–501. doi: 10.7326/0003-4819-131-7-199910050-00003. [DOI] [PubMed] [Google Scholar]
  • 23.Taylor F.C., Cohen H., Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. Bmj. 2001;322:321–326. doi: 10.1136/bmj.322.7282.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Segal J.B., McNamara R.L., Miller M.R., Powe N.R., Goodman S.N., Robinson K.A. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. Cochrane Database Syst Rev. 2001;1 doi: 10.1002/14651858.CD001938. CD001938. [DOI] [PubMed] [Google Scholar]
  • 25.Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients Bmj. 2002;324:71–86. doi: 10.1136/bmj.324.7329.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Ezekowitz M.D., Levine J.A. Preventing stroke in patients with atrial fibrillation. Jama. 1999;281:1830–1835. doi: 10.1001/jama.281.19.1830. [DOI] [PubMed] [Google Scholar]
  • 27.Green C.J., Hadorn D.C., Bassett K., Kazanjian A. Anticoagulation in chronic nonvalvular atrial fibrillation: a critical appraisal and metaanalysis. Can J Cardiol. 1997;13:811–815. [PubMed] [Google Scholar]
  • 28.Hart R.G., Halperin J.L. Atrial fibrillation and stroke: concepts and controversies. Stroke. 2001;32:803–808. doi: 10.1161/01.str.32.3.803. [DOI] [PubMed] [Google Scholar]
  • 29.Van Walraven C., Hart R.G., Singer D.E., Laupacis A., Connolly S., Petersen P. Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis. Jama. 2002;288:2441–2448. doi: 10.1001/jama.288.19.2441. [DOI] [PubMed] [Google Scholar]
  • 30.Fuster V., Ryden L.E., Asinger R.W., Cannom D.S., Crijns H.J., Frye R.L. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation): developed in Collaboration With the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol. 2001;38:1231–1266. doi: 10.1016/s0735-1097(01)01587-x. [DOI] [PubMed] [Google Scholar]
  • 31.Hart R.G., Sherman D.G., Easton J.D., Cairns J.A. Prevention of stroke in patients with nonvalvular atrial fibrillation. Neurology. 1998;51:674–681. doi: 10.1212/wnl.51.3.674. [DOI] [PubMed] [Google Scholar]
  • 32.Albers G.W. Choice of antithrombotic therapy for stroke prevention in atrial fibrillation: warfarin, aspirin, or both? Arch Intern Med. 1998;158:1487–1491. doi: 10.1001/archinte.158.14.1487. [DOI] [PubMed] [Google Scholar]
  • 33.Gage B.F., Fihn S.D., White R.H. Warfarin therapy for an octogenarian who has atrial fibrillation. Ann Intern Med. 2001;134:465–474. doi: 10.7326/0003-4819-134-6-200103200-00011. [DOI] [PubMed] [Google Scholar]
  • 34.Hart R.G., Pearce L.A., McBride R., Rothbart R.M., Asinger R.W. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF I-III clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke. 1999;30:1223–1229. doi: 10.1161/01.str.30.6.1223. [DOI] [PubMed] [Google Scholar]
  • 35.Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia The European Atrial Fibrillation Trial Study Group. N Engl J Med. 1995;333:5–10. doi: 10.1056/NEJM199507063330102. [DOI] [PubMed] [Google Scholar]
  • 36.Launbjerg J., Egeblad H., Heaf J., Nielsen N.H., Fugleholm A.M., Ladefogen K. Bleeding complication to oral anticoagulant therapy:multivariate analysis of 1010 treatment years in 551 outpatients. J Intern Med. 1991;229:351–355. doi: 10.1111/j.1365-2796.1991.tb00358.x. [DOI] [PubMed] [Google Scholar]
  • 37.Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation : a multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial Fibrillation-Embolism Secondary Prevention Cooperative Study Group. Stroke. 2000;31:817–821. doi: 10.1161/01.str.31.4.817. [DOI] [PubMed] [Google Scholar]
  • 38.Gage B.F., Waterman A.D., Shannon W., Boechler M., Rich M.W., Radford M.J. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. Jama. 2001;285:2864–2870. doi: 10.1001/jama.285.22.2864. [DOI] [PubMed] [Google Scholar]
  • 39.Albers G., Dalen J., Laupacis A. Antithrombotic therapy in atrial fibrillation. Chest. 2001;119(Suppl 1):5194–5206. doi: 10.1378/chest.119.1_suppl.194s. [DOI] [PubMed] [Google Scholar]

Articles from Atencion Primaria are provided here courtesy of Elsevier

RESOURCES